Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.03 Million CAD | -20.04% |
| 2022 | 1.29 Million CAD | 0.25% |
| 2021 | 1.28 Million CAD | -39.76% |
| 2020 | 2.13 Million CAD | -49.79% |
| 2019 | 4.25 Million CAD | 452.48% |
| 2018 | 770.51 Thousand CAD | -38.41% |
| 2017 | 1.25 Million CAD | -59.97% |
| 2016 | 3.12 Million CAD | -34.16% |
| 2015 | 4.74 Million CAD | 38.45% |
| 2014 | 3.42 Million CAD | -1.7% |
| 2013 | 3.48 Million CAD | 30.3% |
| 2012 | 2.67 Million CAD | -22.02% |
| 2011 | 3.43 Million CAD | 256.33% |
| 2010 | 963.24 Thousand CAD | 81.41% |
| 2009 | 530.98 Thousand CAD | -50.9% |
| 2008 | 1.08 Million CAD | -8.58% |
| 2007 | 1.18 Million CAD | 1083.0% |
| 2006 | 99.99 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 809.17 Thousand CAD | 10.85% |
| 2024 Q1 | 701.08 Thousand CAD | -32.07% |
| 2024 Q2 | 729.97 Thousand CAD | 4.12% |
| 2023 Q1 | 778 Thousand CAD | -39.72% |
| 2023 Q3 | 1.1 Million CAD | -20.96% |
| 2023 Q2 | 1.39 Million CAD | 79.35% |
| 2023 Q4 | 1.03 Million CAD | -6.42% |
| 2023 FY | 1.03 Million CAD | -20.04% |
| 2022 Q4 | 1.29 Million CAD | -34.06% |
| 2022 Q3 | 1.95 Million CAD | -3.4% |
| 2022 Q1 | 674.85 Thousand CAD | -47.58% |
| 2022 Q2 | 2.02 Million CAD | 200.26% |
| 2022 FY | 1.29 Million CAD | 0.25% |
| 2021 Q4 | 1.28 Million CAD | 11.32% |
| 2021 FY | 1.28 Million CAD | -39.76% |
| 2021 Q2 | 1.41 Million CAD | -8.97% |
| 2021 Q1 | 1.55 Million CAD | -27.17% |
| 2021 Q3 | 1.15 Million CAD | -18.37% |
| 2020 Q1 | 3.93 Million CAD | -7.65% |
| 2020 FY | 2.13 Million CAD | -49.79% |
| 2020 Q3 | 2.58 Million CAD | -24.83% |
| 2020 Q2 | 3.43 Million CAD | -12.61% |
| 2020 Q4 | 2.13 Million CAD | -17.24% |
| 2019 FY | 4.25 Million CAD | 452.48% |
| 2019 Q4 | 4.25 Million CAD | -7.28% |
| 2019 Q2 | 1.27 Million CAD | 165.07% |
| 2019 Q1 | 482.1 Thousand CAD | -37.43% |
| 2019 Q3 | 4.59 Million CAD | 259.28% |
| 2018 Q4 | 770.51 Thousand CAD | -42.7% |
| 2018 FY | 770.51 Thousand CAD | -38.41% |
| 2018 Q3 | 1.34 Million CAD | 49.54% |
| 2018 Q2 | 899.25 Thousand CAD | -22.6% |
| 2018 Q1 | 1.16 Million CAD | -7.13% |
| 2017 Q2 | 2.73 Million CAD | -0.19% |
| 2017 Q1 | 2.74 Million CAD | -12.3% |
| 2017 Q3 | 2.74 Million CAD | 0.26% |
| 2017 FY | 1.25 Million CAD | -59.97% |
| 2017 Q4 | 1.25 Million CAD | -54.38% |
| 2016 FY | 3.12 Million CAD | -34.16% |
| 2016 Q2 | 4.16 Million CAD | -1.45% |
| 2016 Q3 | 3.95 Million CAD | -4.95% |
| 2016 Q1 | 4.22 Million CAD | -11.05% |
| 2016 Q4 | 3.12 Million CAD | -20.98% |
| 2015 Q4 | 4.74 Million CAD | 21.57% |
| 2015 FY | 4.74 Million CAD | 38.45% |
| 2015 Q3 | 3.9 Million CAD | -0.37% |
| 2015 Q2 | 3.91 Million CAD | 9.94% |
| 2015 Q1 | 3.56 Million CAD | 3.97% |
| 2014 Q3 | 3.16 Million CAD | -16.52% |
| 2014 Q2 | 3.78 Million CAD | 2.87% |
| 2014 Q4 | 3.42 Million CAD | 8.37% |
| 2014 FY | 3.42 Million CAD | -1.7% |
| 2014 Q1 | 3.68 Million CAD | 5.62% |
| 2013 Q4 | 3.48 Million CAD | 15.59% |
| 2013 Q3 | 3.01 Million CAD | -7.2% |
| 2013 Q2 | 3.25 Million CAD | 12.88% |
| 2013 Q1 | 2.88 Million CAD | 7.62% |
| 2013 FY | 3.48 Million CAD | 30.3% |
| 2012 Q2 | 3.6 Million CAD | 22.94% |
| 2012 Q4 | 2.67 Million CAD | -16.05% |
| 2012 Q3 | 3.18 Million CAD | -11.59% |
| 2012 Q1 | 2.93 Million CAD | -14.53% |
| 2012 FY | 2.67 Million CAD | -22.02% |
| 2011 FY | 3.43 Million CAD | 256.33% |
| 2011 Q4 | 3.43 Million CAD | -46.91% |
| 2011 Q3 | 6.46 Million CAD | -7.8% |
| 2011 Q1 | 642.87 Thousand CAD | -33.26% |
| 2011 Q2 | 7.01 Million CAD | 990.75% |
| 2010 Q1 | 578.96 Thousand CAD | 9.04% |
| 2010 FY | 963.24 Thousand CAD | 81.41% |
| 2010 Q4 | 963.24 Thousand CAD | 263.55% |
| 2010 Q3 | 264.95 Thousand CAD | -26.87% |
| 2010 Q2 | 362.32 Thousand CAD | -37.42% |
| 2009 Q1 | 1.14 Million CAD | 5.56% |
| 2009 Q3 | 935.64 Thousand CAD | 0.0% |
| 2009 Q4 | 530.98 Thousand CAD | -43.25% |
| 2009 FY | 530.98 Thousand CAD | -50.9% |
| 2008 Q3 | 1.06 Million CAD | -2.15% |
| 2008 FY | 1.08 Million CAD | -8.58% |
| 2008 Q2 | 1.09 Million CAD | -3.76% |
| 2008 Q1 | 1.13 Million CAD | -3.97% |
| 2008 Q4 | 1.08 Million CAD | 1.11% |
| 2007 Q1 | 506.91 Thousand CAD | 0.0% |
| 2007 FY | 1.18 Million CAD | 1083.0% |
| 2007 Q3 | 1.18 Million CAD | 149.52% |
| 2007 Q4 | 1.18 Million CAD | 0.24% |
| 2007 Q2 | 472.92 Thousand CAD | -6.71% |
| 2006 FY | 99.99 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 97.343% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 85.705% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.037% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 90.221% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.207% |
| Mesoblast Limited | 667.9 Million USD | 99.845% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1326.205% |
| Genus plc | 1.02 Billion USD | 99.9% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 24.02% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -106.812% |
| Marizyme, Inc. | 22.01 Million USD | 95.312% |
| ContraFect Corporation | 20.67 Million USD | 95.009% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -64.605% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -164.386% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -170.051% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 27.929% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 75.107% |
| MultiCell Technologies, Inc. | 126.22 USD | -817577.864% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -9.831% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.197% |
| EV Biologics, Inc. | 431.71 Thousand USD | -139.064% |
| Q BioMed Inc. | 3.51 Million USD | 70.642% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 97.066% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -33.923% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -295.011% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1298.113% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.777% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 96.561% |
| Skye Bioscience, Inc. | 11.94 Million USD | 91.356% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 68.848% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 62.42% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 47.295% |
| IMV Inc. | 31.33 Million USD | 96.706% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -50.123% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 60.354% |
| GB Sciences, Inc. | 103.44 Thousand USD | -897.731% |
| Alpha Cognition Inc. | 2.45 Million USD | 57.912% |
| HST Global, Inc. | 1526.00 USD | -67532.569% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Halberd Corporation | 10.13 Thousand USD | -10087.277% |
| Enzolytics Inc. | 361.7 Million USD | 99.715% |
| Resverlogix Corp. | 8.11 Million USD | 87.282% |
| Affymax, Inc. | 7.44 Million USD | 86.134% |
| SYBLEU INC | 330.46 Thousand USD | -212.306% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 45.041% |
| argenx SE | 4.54 Billion USD | 99.977% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 96.307% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 97.836% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -4430.411% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 88.467% |
| AVAX Technologies, Inc. | 7.37 Million USD | 86.01% |
| Zenith Capital Corp. | 7410.00 USD | -13828.111% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.97% |
| Ember Therapeutics, Inc. | 184.00 USD | -560809.239% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -220.713% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -294.88% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.769% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 28.766% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 65.883% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.042% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -11.219% |
| BioStem Technologies, Inc. | 14.56 Million USD | 92.912% |
| ONE Bio Corp. | 70.08 Million USD | 98.527% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1707.673% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -44578.485% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -4.464% |
| Agentix Corp. | 261.39 Thousand USD | -294.837% |
| LadRx Corporation | 2.3 Million USD | 55.281% |
| Cell Source, Inc. | 195.17 Thousand USD | -428.804% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -114.766% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -191.862% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -191.862% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1558.002% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -61.348% |
| Itoco Inc. | 1.4 Million USD | 26.284% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -978.931% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -873.654% |
| Kadimastem Ltd | 2.3 Million USD | 55.207% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1251.695% |
| CytoDyn Inc. | 11.13 Million USD | 90.732% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -621.871% |
| Mobile Lads Corp. | 52.00 USD | -1984655.769% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -5672.22% |
| Qrons Inc. | 420.00 USD | -245631.667% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -167.743% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -86.929% |
| Rebus Holdings, Inc. | 5000.00 USD | -20541.46% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -152.08% |
| International Stem Cell Corporation | 5.39 Million USD | 80.852% |
| Bioxytran, Inc. | 137.63 Thousand USD | -649.846% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 93.12% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 93.775% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1206.422% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -19.359% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 86.27% |
| Neutra Corp. | 2851.00 USD | -36100.386% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 96.815% |
| PureTech Health plc | 693.97 Million USD | 99.851% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 87.213% |
| IXICO plc | 15.84 Million USD | 93.486% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 87.538% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.001% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Cellectis S.A. | 333.99 Million USD | 99.691% |